{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-071430","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.701176+00:00","generated_at":"2026-06-13T23:34:38.690463+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Eloxx reports Phase 2 CF data: ELX-02 shows +2.83% ppFEV1 in 6 responders, supports pivotal trial","bullets":["13 evaluable patients; 6 responders had +2.83% mean ppFEV1 increase at Day 35 vs Day 1.","Overall ppFEV1 change was -0.31% at Day 35; disease progression pre-treatment averaged -4.26%/yr.","Safety follow-up at 28 days showed -2.69% ppFEV1 decline; no treatment-related serious adverse events.","Results bolster decision to advance ELX-02 into pivotal Alport syndrome trial.","Interim topline from 11 patients reported Sep 2022; final analysis confirms activity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-071430","json":"https://secwatch.observer/filing/0001104659-23-071430.json","markdown":"https://secwatch.observer/filing/0001104659-23-071430.md","text":"https://secwatch.observer/filing/0001104659-23-071430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923071430/0001104659-23-071430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465923071430/tm2318799d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T23:34:38.690463+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}